FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, Y.
Right arrow Articles by Culman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, Y.
Right arrow Articles by Culman, J.
(The FASEB Journal. 2006;20:1162-1175.)
© 2006 FASEB

Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats

Yi Zhao, Andreas Patzer, Thomas Herdegen, Peter Gohlke and Juraj Culman1

Institute of Pharmacology, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany

1Correspondence: Institute of Pharmacology, University Hospital of Schleswig-Holstein, Campus Kiel Hospitalstrasse 4 24105 Kiel, Germany. E-mail: juraj.culman{at}pharmakologie.uni-kiel.de

Up-regulation of cyclooxygenase (COX)-2 exacerbates neuronal injury after cerebral ischemia and contributes to neuronal cell death. The present study clarifies the function of cerebral peroxisome-proliferator-activated receptor(s) gamma (PPAR{gamma}) in the expression of COX-2 in neurons of the rat brain after middle cerebral artery occlusion (MCAO) with reperfusion by immunohistochemistry, Western blot, and immunofluorescence staining. In peri-infarct cortical areas the PPAR{gamma} was located in both microglia and neurons, whereas COX-2 was almost exclusively expressed in neurons. PPAR{gamma} immunolabeling reached the peak 12 h after MCAO, whereas the number of COX-2 immunostained cells gradually rose and reached its peak at 48 h. Intracerebroventricular infusion of pioglitazone, an agonist of the PPAR{gamma}, over a 5-day period before and 2 days after MCAO, reduced the infarct size, the expression of tumor necrosis factor {alpha} (TNF-{alpha}), COX-2, and the number of cells positively stained for COX-1 and COX-2 in the peri-infarct cortical regions. COX-2 induction was also attenuated in the ipsilateral but not in the contralateral hippocampus. In primary cortical neurons expressing the PPAR{gamma}, pioglitazone suppressed COX-2 expression in response to oxidative stress. This protective effect was reversed after cotreatment with GW 9662, a selective antagonist of the PPAR{gamma}, clearly demonstrating a PPAR{gamma}-dependent mechanism. Our data provide evidence that activation of neuronal PPAR{gamma} considerably contributes to neuroprotection by prevention of COX-2 up-regulation in vitro and in peri-infarct brain areas.—Zhao, Y., Patzer, A., Herdegen, T., Gohlke, P., Culma, J. Activation of cerebral peroxisome proliferator-activated receptors gamma (PPAR{gamma}) promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats.


Key Words: cerebral ischemia • PPAR{gamma} • pioglitazone • cyclooxygenase-2 • cyclooxygenase-1 • rat




This article has been cited by other articles:


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
M. Collino, N. S.A. Patel, and C. Thiemermann
Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 179 - 197.
[Abstract] [PDF]


Home page
Mol. Pharmacol.Home page
R. Kratzner, F. Frohlich, K. Lepler, M. Schroder, K. Roher, C. Dickel, M. V. Tzvetkov, T. Quentin, E. Oetjen, and W. Knepel
A Peroxisome Proliferator-Activated Receptor {gamma}-Retinoid X Receptor Heterodimer Physically Interacts with the Transcriptional Activator PAX6 to Inhibit Glucagon Gene Transcription
Mol. Pharmacol., February 1, 2008; 73(2): 509 - 517.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Fuenzalida, R. Quintanilla, P. Ramos, D. Piderit, R. A. Fuentealba, G. Martinez, N. C. Inestrosa, and M. Bronfman
Peroxisome Proliferator-activated Receptor {gamma} Up-regulates the Bcl-2 Anti-apoptotic Protein in Neurons and Induces Mitochondrial Stabilization and Protection against Oxidative Stress and Apoptosis
J. Biol. Chem., December 21, 2007; 282(51): 37006 - 37015.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. Ceolotto, A. Gallo, I. Papparella, L. Franco, E. Murphy, E. Iori, E. Pagnin, G. P. Fadini, M. Albiero, A. Semplicini, et al.
Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent Mechanism
Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2627 - 2633.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
R. Luna-Medina, M. Cortes-Canteli, S. Sanchez-Galiano, J. A. Morales-Garcia, A. Martinez, A. Santos, and A. Perez-Castillo
NP031112, a Thiadiazolidinone Compound, Prevents Inflammation and Neurodegeneration under Excitotoxic Conditions: Potential Therapeutic Role in Brain Disorders
J. Neurosci., May 23, 2007; 27(21): 5766 - 5776.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Iwashita, Y. Muramatsu, T. Yamazaki, M. Muramoto, Y. Kita, S. Yamazaki, K. Mihara, A. Moriguchi, and N. Matsuoka
Neuroprotective Efficacy of the Peroxisome Proliferator-Activated Receptor {delta}-Selective Agonists in Vitro and in Vivo
J. Pharmacol. Exp. Ther., March 1, 2007; 320(3): 1087 - 1096.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
P. Pacher, J. S. Beckman, and L. Liaudet
Nitric Oxide and Peroxynitrite in Health and Disease
Physiol Rev, January 1, 2007; 87(1): 315 - 424.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by The Federation of American Societies for Experimental Biology.